MAR-ROSUVASTATIN 5 MG
ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 5 MG · DIN 02413051 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-ROSUVASTATIN?
MAR-ROSUVASTATIN 5 MG contains ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02413051, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Jun-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-ROSUVASTATIN used for?
MAR - ROSUVASTATIN (rosuvastatin calcium) is indicated in adults as an adjunct to diet, at least equivalent to the Adult Treatment Panel III (ATP III TLC diet), for the reduction of elevated total cholesterol (Total - C), LDL - C, ApoB, the Total - C/HDL - C ratio and triglycerides (TG) and for increasing HDL - C; in hyperlipidemic and dyslipidemic conditions, when response to diet and exercise alone has been inadequate including: Primary hypercholesterolemia (Type IIa including heterozygous familial hypercholesterolemia and severe non - familial hypercholesterolemia), Combined (mixed) dyslipidemia (Type IIb), Homozygous familial hypercholesterolemia where rosuvastatin is used either alone or as an adjunct to diet and other lipid lowering treatments such as apheresis. In adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, MAR - ROSUVASTATIN is indicated to: Reduce the risk of nonfatal myocardial infarction, Reduce the risk of nonfatal stroke, Reduce the risk of coronary artery revascularization. In pediatric patients (10 to <18 years) with heterozygous familial hypercholesterolemia, MAR-ROSUVASTATIN is indicated as an adjunct to diet to reduce elevated total cholesterol (Total - C), LDL - C and ApoB in boys and girls who are at least one year post - menarche, when response to diet alone has been inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02413051 |
|---|---|
| Brand name | MAR-ROSUVASTATIN |
| Generic / active ingredient | ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 5 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA07 ROSUVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Jun-2023 |
| Original market date | 2014-06-26 00:00:00 |
How is it stored and handled?
null
How is it supplied?
blister packs of 30 tablets (3 blister strip of 10 tablets each) and high-density polyethylene (HDPE) bottles of 100 and 500 tablets each
Is ROSUVASTATIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA07 ROSUVASTATIN. 84 of 152 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ROSUVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438925 |
| ACH-ROSUVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438933 |
| ACH-ROSUVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438941 |
| ACH-ROSUVASTATIN | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438917 |
| AG-ROSUVASTATIN CALCIUM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500140 |
| AG-ROSUVASTATIN CALCIUM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500159 |
| AG-ROSUVASTATIN CALCIUM | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500167 |
| AG-ROSUVASTATIN CALCIUM | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500132 |
| APO-ROSUVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02337983 |
| APO-ROSUVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02337991 |
Who else supplies ROSUVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ROSUVASTATIN appears in 2950 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.